I. Introduction {#s0005}
===============

Rabies continues to present a serious burden for both public health and the global economy. It causes more than 55,000 human deaths, and more than 10 million people undergo postexposure prophylaxis (PEP) every year around the globe ([@bb0215], [@bb0235]). Most human cases occur in the developing countries of Asia and Africa, where canine rabies is endemic and resources are limited ([@bb0075]). In more developed countries, human rabies has dramatically declined during the past 60 years as a direct consequence of routine vaccination of pet animals ([@bb0190]). However, wildlife rabies has emerged as a major threat ([@bb0250]). Despite extensive investigation over more than 100 years, the pathogenetic mechanisms by which infection of street rabies virus (RABV) results in neurological diseases and death in humans are not well understood. Neuronal pathology or damage in the central nervous system (CNS) is limited in rabies patients with only mild inflammation ([@bb0245], [@bb0260]). However, laboratory-attenuated RABV induces extensive inflammation and neuronal degeneration in experimental animals ([@bb0245], [@bb0375]). It is only recently that the roles of chemokines in rabies pathogenesis and protection have been investigated. This chapter will summarize recent research activities in this area.

II. Chemokines {#s0010}
==============

Chemokines are a family of structurally related proteins that are expressed by almost all types of nucleated cells and mediate leukocyte activation and/or chemotactic activities ([@bb0400]). The majority of chemokines have molecular masses of 8--14 kDa and share approximately 20--50% sequence homology among each other at the protein level ([@bb0090], [@bb0400]). Chemokine proteins also share common gene sequences and tertiary structures, and all chemokines possess a number of conserved cysteine residues involved in intramolecular disulfide bond formation. Chemokines can be divided into four major subfamilies based on cysteine signature motifs: the C, CC, CXC, and CX3C families ([Table I](#t0005){ref-type="table"} ) ([@bb0090], [@bb0400]). Chemokines in which the C1 and C2 cysteine residues are adjacent are called CC chemokines and include RANTES, MCP-1, TARC, and eotaxin. Many CC chemokines exert their effects on monocytes and macrophages, but CC chemokines have been shown to be important for dendritic cell (DC) chemotaxis and some CC chemokines appear to act preferentially on Th2-type T cells ([@bb0090], [@bb0400]). Chemokines in which the C1 and C2 cysteine residues are separated by a single amino acid are called CXC chemokines and include IL-8, IP-10, I-TAC, and SDF-1. CXC chemokines act as chemoattractants for neutrophils and have been shown to be important mediators of T- and B-lymphocyte chemotaxis ([@bb0090], [@bb0400]). The C subfamily chemokine, lymphotactin, is a potent T-lymphocyte chemoattractant, and fractalkine is the only member of CX3C chemokine subfamily, which may chemoattract mononuclear leukocytes ([@bb0100]). Chemokines are highly basic proteins and contain at least four cysteine residues that form two disulfide bonds ([@bb0350]). This property may help mediate stable gradient formation by promoting interactions of chemokines with sulfated proteins and proteoglycans ([@bb0040]). Chemokines may also be divided into inflammatory chemokines and homeostatic chemokines in terms of biological features and cellular distribution of chemokine receptors ([@bb0255]). The former are secreted by resident and infiltrated cells on inflammatory stimuli or contacting with pathogenic agents. These chemokines are responsible for recruiting cells related to inflammatory reactions ([@bb0140]). However, homeostatic chemokines are involved in maintaining trafficking and positioning of immune cells involved in adaptive immunity and antigen presentation in secondary lymphoid organs ([@bb0255], [@bb0315]).Table IChemokines and chemokine receptorsSystematic nameHuman/mouse ligandChemokine receptorC familyLymphotactinXCR1CC familyCCL1I-309CCR8CCL2MCP-1CCR2, CCR4CCL3MIP-1αCCR1, CCR5CCL4MIP-1βCCR5CCL5RANTESCCR1, CCR3, CCR5CCL6C10, MRP-1CCR1CCL7MCP-3CCR1, CCR2, CCR3CCL8MCP-2CCR1, CCR2B, CCR5CCL9MRP-2, MIP-1γCCR1CCL11eotaxin-1CCR2, CCR3, CCR5CCL12MCP-5CCR2CCL13MCP-4CCR2, CCR3, CCR5CCL14HCC-1CCR1CCL15HCC-2CCR1, CCR3CCL16HCC-4CCR1, CCR2, CCR5, CCR8CCL17TARCCCR4CCL18PARCUnknownCCL19MIP-3βCCR7CCL20LARC, MIP-3αCCR6CCL216Ckine, SLC, exodus-2CCR7CCL22MDCCCR4CCL23MPIF-1CCR1CCL24MPIF-2, eotaxin-2CCR3CCL25TECKCCR9CCL26Eotaxin-3CCR3CCL27ILC, CTACKCCR10CCL28MECCCR3, CCR10CXC familyCXCL1GROα, MSGA-αCXCR2CXCL2GROβ, MSGA-βCXCR2CXCL3GROγ, MSGA-γCXCR2CXCL4PF4CXCR3CXCL5ENA-78CXCR2CXCL6GCP-2CXCR1, CXCR2CXCL7NAP-2CXCR2CXCL8IL-8CXCR1, CXCR2CXCL9MigCXCR3CXCL10IP-10CXCR3CXCL11I-TAC, IP-9CXCR3CXCL12SDF-2CXCR4CXCL13BLCCXCR5CXCL14BRAKUnknownCXCL15LungkineUnknownCX3CCX3CL1FractalkineCX3CR1

Chemokines mediate their effects by binding to the seven transmembrane G-protein-coupled cell-surface receptors ([Table I](#t0005){ref-type="table"}) ([@bb0300], [@bb0400]). Upon binding, the chemokine receptors initiate cellular signaling through changes in intracellular concentrations of calcium and cAMP. Many cellular chemokine receptors can bind more than one chemokine with similar affinities. For example, the chemokine receptors CCR1 and CCR5 may bind RANTES, MIP-1α, and MIP-1β, whereas the chemokine receptors CXCR1 and CXCR2 may bind IL-8 ([@bb0090], [@bb0400]). Based on the chemokine subfamilies, chemokine receptors have been named CCR1-9, CXCR1-5, XCR1, and CX3R1 ([@bb0400]). Several chemokines can bind to one receptor, and one ligand can bind to more than one receptor ([@bb0350]). These intricate complex interactions can provide adequate host defenses against infection with pathogens. However, viruses may mimic chemokine receptors to evade host defense mechanisms ([@bb0100]).

III. The Role of Chemokines in the CNS When Infected by Viruses {#s0015}
===============================================================

A recent review has provided an elegant illustration of the roles of chemokines in the CNS after viral infections ([@bb0155]). Viral infections of the CNS can result in a temporal expression of several chemokines and chemokine receptors by CNS resident cells (astrocytes, microglia, as well as neurons) and by inflammatory cells infiltrated into the CNS ([@bb0155], [@bb0270], [@bb0295]). Astrocytes and microglia are the dominant source of chemokines following infection with neurotropic viruses ([@bb0155]). Robust expression of numerous CC chemokines such as CCL2, CCL3, CCL4, and CCL5 ([@bb0400]) was observed following infection with measles virus ([@bb0280]), mouse hepatitis virus (MHV) ([@bb0170]), and human coronavirus ([@bb0020]). Infection of rat astrocytes and microglia with paramyxoviruses resulted in rapid expression of mRNA transcripts for CCL5 and CXCL10 ([@bb0070], [@bb0355]). In some virus infections, chemokine expression was found in a particular cell type. For example, CXCL10 was exclusively secreted by astrocytes in the neural parenchyma, but not by microglia in the brain or recruited bone marrow-derived cell types after infection with lymphocytic choriomeningitis virus (LCMV) ([@bb0030]). Induction of chemokine gene expression is promoted by toll-like receptors (TLRs) when recognizing viral DNA or RNA ([@bb0095], [@bb0330]). For example, TLR2 and TLR3 cooperation leads to the expression of macrophage chemoattractants CCL2 and CCL5 during infection with Theiler\'s murine encephalitis virus (TMEV) ([@bb0330]). However, TLR2 and TLR9 mediate chemokine expression during HSV-1 infection ([@bb0005], [@bb0195]).

The major activity of chemokines is modulating leukocyte trafficking into the CNS ([@bb0155]). Both neuroprotective and neuropathologic effects of chemokine expression in the CNS have been reported, and these are largely due to attracting T lymphocytes and macrophages ([@bb0055], [@bb0200]). On one hand, infiltration and antiviral activity of T lymphocytes are requisite for viral clearance and survival. For example, CXCL10 expressed in the CNS after infection with neurotropic viruses attracts activated T lymphocytes bearing the receptor CXCR3 ([@bb0385]). It has been reported that in many virus infections such as herpes simplex virus (HSV), MHV, and West Nile virus (WNV), ablation of CXCL10 expression by either depletion with neutralization antibodies or genetic knockout dramatically reduces infiltration of T cell into the CNS, which results in inefficient viral control and severe disease ([@bb0335], [@bb0340], [@bb0385]). Another chemokine CCL5 and its receptors, CCR5, have also been found to promote leukocyte trafficking into the CNS and control of HSV and WNV infections ([@bb0110], [@bb0345]). CCR5 knockout showed an increased risk for symptomatic WNV infection ([@bb0115]). On the other hand, excessive chemokine secretion and accumulation of leukocytes within the CNS lead to the development of neuropathology. It is well known that fatal meningoencephalitis induced by LCMV infection is mediated by infiltration of virus-specific cytotoxic T lymphocytes (CTLs) ([@bb0085], [@bb0175]). Genetic silencing of CXCL10 or its receptor CXCR3 reduces the infiltration of CD8+ T cells, conferring either partial or near complete protection from immunopathology and death ([@bb0025], [@bb0135]). Demyelinating disease during MHV infection is largely due to sustained CXCL10 and CCL5 expression, and abrogation of expression of either these chemokine reduces infiltration of immune cells, disease severity, and demyelination ([@bb0105], [@bb0205]). There are numerous examples of neuroprotective and neuropathologic activities associated with the expression of chemokines during viral infections ([@bb0155]).

IV. Induction of Chemokine Expression in RABV Infections {#s0020}
========================================================

RABV induces a fatal neurological disease in humans and animals, and the roles of chemokines in rabies are just beginning to emerge. Using oligonucleotide microarray, we reported that chemokines were upregulated in the mouse brain after infection with laboratory-attenuated, but not with street virus ([@bb0360]). This includes both the CC and CXC subfamilies of proinflammatory chemokines. Among these chemokines, MIP-1α, RANTES, and IP-10 were increased more than 50- to 100-fold in infected versus sham-infected mice ([@bb0180], [@bb0360]). Further, the protein level of chemokines CXCL10 and CCL5 was dramatically upregulated in neuroblastoma cells after infection with laboratory-attenuated RABV ([@bb0220]). It has also been reported that chemokine CXCL-10 and cytokines (IL-6, IFN-γ) were upregulated at the time of clinical disease in the CNS of mice infected with European bat lyssaviruses (EBLV) types 1 and 2 ([@bb0210]). Interestingly, a lower but significant increase of CXCL10 was also observed in the salivary glands ([@bb0210]). CXCL10 has also been reported to be activated by macrophages and microglia infected with RABV ([@bb0265], [@bb0270]).

The increased expression of chemokines in RABV infection in the CNS resulted in infiltration of inflammatory cells, induction of apoptosis, and enhancement of blood--brain barrier (BBB) permeability in mice infected with fixed (or laboratory-attenuated) RABV ([@bb0065], [@bb0180], [@bb0320], [@bb0360], [@bb0390]). As a consequence, fixed RABV could be cleared from the CNS of mice when infected with low doses ([@bb0150], [@bb0320]). It is, therefore, hypothesized that induction of innate immunity, particularly with chemokines and IFN, is one of the mechanisms for RABV attenuation. However, mice infected with high dose of fixed RABV die with excessive inflammation in the CNS ([@bb0320], [@bb0360]). Therefore, the pathogenetic mechanisms by which street and fixed RABV induce disease are different. In animals infected with a high dose of fixed RABV, it is the expression of chemokines and other innate immune molecules that results in the enhancement of BBB permeability and infiltration of inflammatory cells into the CNS, which is ultimately responsible for the demise of the infected animals ([@bb0180], [@bb0360]). On the contrary, street RABV invades the CNS without stimulating the innate immune responses. Although the exact mechanisms by which street RABV causes rabies are not known, it has been hypothesized that RABV induces CNS dysfunction ([@bb0050]). Recently, we have observed that infection of street RABV inhibits the expression of proteins involved in the fusion between neurotransmitter vesicle membrane and the presynaptic membrane, resulting in massive accumulation of neurotransmitter vesicles in presynapses ([@bb0045]). These observations may also explain why very little neuronal pathology or damage is observed in the CNS of rabies patients ([@bb0245], [@bb0260]), whereas laboratory-attenuated RABV induces extensive inflammation and neuronal degeneration in experimentally infected animals ([@bb0245], [@bb0375]).

V. Overexpression of Chemokines Can Benefit the Host If the Expression Is Transient While It Harms the Host If the Expression Is Persistent During RABV Infections {#s0025}
==================================================================================================================================================================

To further explore the role of chemokines in RABV infections, chemokines MIP-1α, RANTES, or IP-10 were individually expressed in the genome of RABV HEP-Flurry strain ([@bb0390], [@bb0395]). It was found that although the expression of MIP-1α further reduced RABV pathogenicity, expression of RANTES or IP-10 enhanced RABV pathogenicity in the mouse model. The differences in pathogenicity induced by these recombinant RABVs are not due to the rate of virus replication, but rather due to the level and the duration of the expression of chemokines ([@bb0390]). HEP-MIP1α induced the expression of MIP-1α in the mouse model but subsided quickly. In addition, only low to moderate levels of other chemokines were induced. Likewise, only low and transient infiltration of inflammatory cells (macrophages, neutrophils, and T cells) was observed in the infected mice. In contrast, HEP-RANTES and particularly HEP-IP10 induced not only high and persistent expression of the intended chemokines but also high expression of other chemokines. High and persistent infiltration of inflammatory cells was also observed in the CNS, which could produce neurotoxins, free radicals, and proinflammatory cytokines, causing CNS destruction ([@bb0150], [@bb0390]). HEP-MIP1α enhanced the BBB permeability temporarily, while HEP-RANTES and HEP-IP10 induced more extensive and prolonged enhancement of BBB permeability. Further, HEP-IP10 induced BBB permeability to the extent that allowed large molecules (10 kDa) to enter the CNS. Although the consequence is not entirely clear, this may have allowed more inflammatory cells or other toxic substances enter into the CNS. Thus, these studies indicate that transient expression of chemokines may help attenuate RABV, whereas high and persistent expression of these chemokines, particularly IP-10, may be harmful to the host during RABV infections.

VI. Chemokines Expression Correlates with the Activation of Dendritic Cells and Enhancement of Adaptive Immunity {#s0030}
================================================================================================================

As chemokines play roles as attractants of naïve and effector T cells ([@bb0255]), these recombinant RABV expressing chemokines were tested for their ability to enhance adaptive immunity ([@bb0390], [@bb0395]). Although overexpression of MIP-1α further attenuated RABV ([@bb0395]), it enhanced the adaptive immune responses by stimulating the production of high levels of virus-neutralizing antibodies (VNA). As MIP-1α is one of the major chemoattractants for monocytes, especially immature DCs and macrophages ([@bb0010], [@bb0225], [@bb0230]), it is possible that expression of MIP-1α recruits/activates DCs. Indeed, it was found that overexpression of MIP-1α resulted in the induction of a strong innate immune response at the local site and recruitment/activation of DCs as well as B cells in the draining lymph nodes and the peripheral blood, leading to the production of high levels of VNA ([@bb0395]). DCs are the most potent antigen presenting cells (APCs) ([@bb0035]), which process antigen, migrate to the T cell zone and stimulate the activation of antigen-specific naïve T cells. Activated T cells stimulate the proliferation and differentiation of antigen-specific naïve B cells into antibody-producing plasma cells ([@bb0060]).

To confirm that recruitment/activation of DCs is the major step in the induction of VNA in RABV immunization, DC-recruitment/activation molecules such as macrophage-derived chemokine (MDC) and granulocyte-macrophage colony-stimulating factor (GM-CSF), in addition to MIP-1α, were individually expressed in the RABV LBNSE strain ([@bb0900]). MDC is known to preferentially attract Th2 cells and regulatory T cells via CCR4 ([@bb0160], [@bb0165], [@bb0380]). It is also a potent chemoattractant for additional cell types including DCs ([@bb0015], [@bb0120]). MDC produced by DCs attracts CCR4-bearing activated (or memory) T cells to enhance immune responses and increase effector functions ([@bb0370]), and it may allow for T--B cell interaction with subsequent formation of germinal centers ([@bb0325]). GM-CSF regulates the production and functional activation of hemopoietic cells such as monocyte/macrophages and all granulocytes ([@bb0240]) and is a cytokine responsible for the recruitment, activation, and maturation of APC ([@bb0125]). Each of these recombinant viruses stimulated more maturation/activation of murine bone marrow-derived DCs *in vitro* and more recruitment and/or activation of DCs, mature B cells as well as T cells in the periphery than the parent virus, which leads to higher levels of VNA and better protection ([@bb0900]). Thus, our data suggest that the expression of chemokines can result in recruitment/activation of DCs, thus enhancing RABV immunogenicity and protection. Chemokines have been used as an adjuvant by incorporating into vaccine preparations to stimulate innate and adaptive immune responses ([@bb0130], [@bb0185]). Coadministration of chemokine and DNA encoding viral protective antigens increases trafficking of mature DCs into the secondary lymphoid tissues, presenting processed viral antigen to naïve T cells and provides protective immunity against virus challenge. RANTES, MCP-1, MIP-1β, and TRANCE have been used together with a truncated secreted version of the RABV glycoprotein in plasmid expression DNA vaccine to enhance immune responses ([@bb0290]). Together, these observations suggest that recombinant RABV expressing chemokines could be developed as potential vaccine candidates.

VII. Recombinant RABV Expressing Chemokines/Cytokines Can Be Used Effectively to Prevent the Development of Rabies {#s0035}
==================================================================================================================

These recombinant RABV expressing chemokines/cytokines were also tested to determine whether they have the ability to prevent animals from developing rabies. Adult mice were infected with a lethal dose of street RABV and then treated with recombinant RABV at different time points after infection ([@bb0365], [@bb0080]). As shown in [Fig. 1](#f0005){ref-type="fig"} , 60--70% of the mice intracerebrally treated with recombinant RABV expressing MDC, IP-10, MIP-1α, or GM-CSF at day 4 after infection with street RABV (a Mexican dog virus, DRV) were protected from developing rabies. The protection rate in mice treated with live recombinant RABV was significantly higher than that in sham-treated mice (20%). In contrast, treatment with UV-inactivated RABV did not provide significantly better protection than sham-treated mice despite the fact that VNAs were induced in these mice. Surprisingly, recombinant RABV expressing RANTES did not protect mice from developing rabies in these mice. Treatment with recombinant RABV by other routes (intramuscular, intradermal, or intranasal) was less effective ([@bb0365]). It was found that intracerebral treatment of mice with these recombinant RABVs induced significantly higher levels of chemokine/cytokine expression in the CNS and in the periphery, infiltration of inflammatory and immune cells into the CNS, and enhancement of BBB permeability than sham-treated mice or mice treated with UV-inactivated RABV. These studies indicate that there are two important factors for protection: VNA in the periphery and enhanced BBB permeability. To demonstrate this is the case, mice were treated with a chemokine (chemoattractant protein-1, MCP-1) with a dose known to enhance BBB permeability. Indeed, this treatment increased the protective efficacy of UV-inactivated RABV, but not in sham-treated mice. These data confirm that chemokines can induce infiltration of inflammatory cells in the CNS and thus enhance the BBB permeability, which allows immune effectors (VNA) enter into the CNS to clear the virus and prevent the development of rabies.Figure 1Recombinant RABVs expressing chemokines/cytokines prevent the development of rabies in the mouse model. ICR mice (4--6 weeks of age) were infected intramuscularly with street DRV and treated intracranially 4 days later with various recombinant RABVs or medium. Mice were observed daily for 2 weeks, and the survivorship was calculated and analyzed statistically.

BBB is a separation of circulating blood and CSF in the CNS and protects the CNS tissues from circulating cells and factors ([@bb0275]). The enhancement of BBB permeability and inflammatory cells infiltration is often associated with pathological changes in the CNS. However, transiently increased BBB permeability has been found to be helpful in clearance of the attenuated RABV from the CNS ([@bb0285]). Highly pathogenic RABV is correlated with the inability of infected animals to enhance BBB permeability and deliver immune effectors into the CNS ([@bb0310]). Further studies have shown that lethal infection with pathogenic RABV could be prevented by increasing BBB permeability in infected animals through the induction of an autoimmune CNS inflammatory response that facilitates immune effectors entry into the CNS tissue and promotes virus clearance ([@bb0305]). Chemokines can help enhance the BBB permeability by inducing inflammatory responses in the CNS, thus aiding immune effectors enter into and clear the virus from the CNS. One of the questions that remains unanswered in these studies is whether the immune effectors (in this case, VNA) need to be produced in the CNS as has been proposed ([@bb0145], [@bb0150]) or whether VNA produced in the periphery and transported to the CNS is just as effective. Future studies should be directed to address this issue.

VIII. Summary {#s0040}
=============

This chapter summarizes recent studies on the role of chemokines in rabies pathogenesis and protection. It has been found that laboratory-adapted RABV is capable of inducing chemokine expression as part of innate immune responses, which is beneficial to the host by initiating infiltration of inflammatory cells into the CNS, enhancing the BBB permeability, and clearing the virus from the CNS ([@bb0180], [@bb0320], [@bb0360]). This is especially important when animals are infected with low doses of laboratory-adapted RABV. However, street RABV fails to induce the expression of chemokines and other innate immune molecules, leading to unblocked invasion of the virus into the CNS ([@bb0180], [@bb0320], [@bb0360]). However, excessive expression of chemokines and other innate immune molecules could induce neurological diseases by inducing extensive inflammation in the CNS when animals are infected with high doses of fixed RABV ([@bb0180], [@bb0320], [@bb0360]). Thus, expression of chemokines has both protective and pathogenetic roles in RABV infections. This contention has been further confirmed by overexpression of some of the chemokines ([@bb0390]). Overexpression of MIP-1α further attenuates RABV, while overexpression of RANTES and IP-10 increases RABV pathogenicity ([@bb0390]). However, overexpression of MIP-1α enhances the immunogenicity of RABV, and the recruitment/activation of DCs is the possible mechanism for the enhanced immunogenicity ([@bb0395]). Indeed, overexpression of chemokines or cytokines with the ability to activate DCs increased RABV immunogenicity and provided better protection ([@bb0900]; [@bb0395]). Further, recombinant RABV expressing chemokines/cytokines can be used to prevent the development of rabies in the mouse model ([@bb0365]). Therefore, recombinant RBAVs expressing chemokines/cytokines could have the potential to be used not only for pre- and postexposure immunization but also for therapy in clinical rabies.

This work is supported partially by Public Health Service Grant AI-051560 from the National Institute of Allergy and Infectious Diseases.
